As the leading cause of death among type 2 diabetic patients , coronary heart disease is prevalent in women and younger patients

T ype 2 diabetes is associated with a threeto fourfold increase in coronary heart disease (CHD) risk,1,2 which is particularly evident in younger age groups and women. Diabetic women lose much of the CHD protection seen in nondiabetic women. Type 2 diabetic patients have a 50% greater in-hospital mortality and a twofold increased rate of death within 2 years of surviving a myocardial infarction. CHD is the leading cause of death among type 2 diabetic patients. Much of the increased disease is associated with wellcharacterized risk factors for CHD like lipids and lipoprotein abnormalities.3,4 The combination of elevated triglycerides (TG), low HDL cholesterol and relatively normal LDL cholesterol carried in small, dense, cholesterol-poor LDL particles, has been called diabetic dyslipidemia. Significant evidence supports a key role for insulin resistance in the development of this condition.5 Nondiabetic insulin resistant patients have lipid profiles nearly identical to those seen in the majority of type 2 diabetic patients. In this review, we look at the role of insulin resistance in the regulation of TG.

[1]  M. Kashyap,et al.  Management of the metabolic syndrome-nicotinic acid. , 2004, Endocrinology and metabolism clinics of North America.

[2]  B. Patterson,et al.  Rate of production of plasma and very-low-density lipoprotein (VLDL) apolipoprotein C-III is strongly related to the concentration and level of production of VLDL triglyceride in male subjects with different body weights and levels of insulin sensitivity. , 2004, The Journal of clinical endocrinology and metabolism.

[3]  E. Fisher,et al.  Lipid peroxidation and oxidant stress regulate hepatic apolipoprotein B degradation and VLDL production. , 2004, The Journal of clinical investigation.

[4]  K. Yasunaga,et al.  Regulation of Hepatic Apolipoprotein B-lipoprotein Assembly and Secretion by the Availability of Fatty Acids , 2004, Journal of Biological Chemistry.

[5]  Luquan Wang,et al.  Materials and Methods Figs. S1 to S4 Tables S1 and S2 References Niemann-pick C1 like 1 Protein Is Critical for Intestinal Cholesterol Absorption , 2022 .

[6]  M. Beylot,et al.  Contribution of hepatic de novo lipogenesis and reesterification of plasma non esterified fatty acids to plasma triglyceride synthesis during non-alcoholic fatty liver disease. , 2003, Diabetes & metabolism.

[7]  C. Ballantyne,et al.  Possible differences between fibrates in pharmacokinetic interactions with statins. , 2003, Archives of internal medicine.

[8]  T. Rabelink,et al.  Thiazolidinediones and Blood Lipids in Type 2 Diabetes , 2003, Arteriosclerosis, thrombosis, and vascular biology.

[9]  G. Crepaldi,et al.  Relevance of hepatic lipase to the metabolism of triacylglycerol-rich lipoproteins. , 2003, Biochemical Society transactions.

[10]  M. Taskinen.  Diabetic dyslipidaemia: from basic research to clinical practice* , 2003, Diabetologia.

[11]  K. Anwar,et al.  Microsomal triglyceride transfer protein: a multifunctional protein. , 2003, Frontiers in bioscience : a journal and virtual library.

[12]  B. Brewer,et al.  Liver-specific disruption of PPARgamma in leptin-deficient mice improves fatty liver but aggravates diabetic phenotypes. , 2003, The Journal of clinical investigation.

[13]  R. Eckel,et al.  Lipoprotein lipase : genetics , lipid uptake , and regulation , 2002 .

[14]  G. Lewis,et al.  Fasting and Postprandial Overproduction of Intestinally Derived Lipoproteins in an Animal Model of Insulin Resistance , 2002, The Journal of Biological Chemistry.

[15]  E. Fisher,et al.  Complexity in the Secretory Pathway: The Assembly and Secretion of Apolipoprotein B-containing Lipoproteins* , 2002, The Journal of Biological Chemistry.

[16]  Joseph L Goldstein,et al.  SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. , 2002, The Journal of clinical investigation.

[17]  R. Zechner,et al.  Hormone-sensitive Lipase Deficiency in Mice Changes the Plasma Lipid Profile by Affecting the Tissue-specific Expression Pattern of Lipoprotein Lipase in Adipose Tissue and Muscle* , 2002, The Journal of Biological Chemistry.

[18]  I. G. Fantus,et al.  Hepatic Very Low Density Lipoprotein-ApoB Overproduction Is Associated with Attenuated Hepatic Insulin Signaling and Overexpression of Protein-tyrosine Phosphatase 1B in a Fructose-fed Hamster Model of Insulin Resistance* , 2002, The Journal of Biological Chemistry.

[19]  H. Ginsberg,et al.  Post-transcriptional Stimulation of the Assembly and Secretion of Triglyceride-rich Apolipoprotein B Lipoproteins in a Mouse with Selective Deficiency of Brown Adipose Tissue, Obesity, and Insulin Resistance* , 2001, The Journal of Biological Chemistry.

[20]  P. Wilson,et al.  Diabetes mellitus and coronary heart disease. , 2001, Endocrinology and metabolism clinics of North America.

[21]  B. Egan,et al.  Insulin resistance and cardiovascular disease. , 2001, American journal of hypertension.

[22]  Diabetes Atherosclerosis Intervention Study Investigators.  Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study , 2001, The Lancet.

[23]  P. Stillemark-Billton,et al.  Intracellular assembly of VLDL: two major steps in separate cell compartments. , 2000, Trends in cardiovascular medicine.

[24]  R. Hammer,et al.  Decreased IRS-2 and increased SREBP-1c lead to mixed insulin resistance and sensitivity in livers of lipodystrophic and ob/ob mice. , 2000, Molecular cell.

[25]  D. Rudy,et al.  Mechanisms of Hepatic Very Low Density Lipoprotein Overproduction in Insulin Resistance , 2000, The Journal of Biological Chemistry.

[26]  B. Sobel,et al.  A Review of Metabolic and Cardiovascular Effects of Oral Antidiabetic Agents: Beyond Glucose-Level Lowering , 1999, Journal of cardiovascular risk.

[27]  R. Davis,et al.  Cell and molecular biology of the assembly and secretion of apolipoprotein B-containing lipoproteins by the liver. , 1999, Biochimica et biophysica acta.

[28]  M. Hellerstein.  De novo lipogenesis in humans: metabolic and regulatory aspects , 1999, European Journal of Clinical Nutrition.

[29]  A. Cooper.  Hepatic uptake of chylomicron remnants. , 1997, Journal of lipid research.

[30]  G. Lewis.  Fatty acid regulation of very low density lipoprotein production. , 1997, Current opinion in lipidology.

[31]  M. Taskinen,et al.  Defective regulation of triglyceride metabolism by insulin in the liver in NIDDM , 1997, Diabetologia.

[32]  G. Siemeister,et al.  SREBP-1 Mediates Activation of the Low Density Lipoprotein Receptor Promoter by Insulin and Insulin-like Growth Factor-I (*) , 1996, Journal of Biological Chemistry.

[33]  G. Gibbons,et al.  VLDL output by hepatocytes from obese Zucker rats is resistant to the inhibitory effect of insulin. , 1995, The American journal of physiology.

[34]  R. Krauss,et al.  LDL density and atherosclerosis. , 1995, JAMA.

[35]  J. Sparks,et al.  Insulin regulation of triacylglycerol-rich lipoprotein synthesis and secretion. , 1994, Biochimica et biophysica acta.

[36]  G. Lewis,et al.  Effects of Acute Hyperinsulinemia on VLDL Triglyceride and VLDL ApoB Production in Normal Weight and Obese Individuals , 1993, Diabetes.

[37]  I. Goldberg,et al.  Increased plasma and renal clearance of an exchangeable pool of apolipoprotein A-I in subjects with low levels of high density lipoprotein cholesterol. , 1993, The Journal of clinical investigation.

[38]  B. Howard.  Diabetes and Plasma Lipoproteins in Native Americans: Studies of the Pima Indians , 1993, Diabetes Care.

[39]  H. Ginsberg.  Lipoprotein Physiology in Nondiabetic and Diabetic States: Relationship to Atherogenesis , 1991, Diabetes Care.

[40]  E. Schaefer,et al.  Measurement of very low density and low density lipoprotein apolipoprotein (Apo) B-100 and high density lipoprotein Apo A-I production in human subjects using deuterated leucine. Effect of fasting and feeding. , 1990, The Journal of clinical investigation.

[41]  A. Cooper,et al.  Regulation of apoprotein synthesis and secretion in the human hepatoma Hep G2. The effect of exogenous lipoprotein. , 1988, The Journal of biological chemistry.

[42]  A. Kissebah.  Low density lipoprotein metabolism in non-insulin-dependent diabetes mellitus. , 1987, Diabetes/metabolism reviews.

[43]  N. Le,et al.  Regulation of the production and catabolism of plasma low density lipoproteins in hypertriglyceridemic subjects. Effect of weight loss. , 1985, The Journal of clinical investigation.

[44]  A. Kissebah,et al.  Role of insulin resistance in adipose tissue and liver in the pathogenesis of endogenous hypertriglyceridaemia in man , 1976, Diabetologia.

[45]  D. Porte,et al.  Evidence for a common, saturable, triglyceride removal mechanism for chylomicrons and very low density lipoproteins in man. , 1973, The Journal of clinical investigation.

[46]  P. Barter,et al.  Precursors of plasma triglyceride fatty acids in obesity. , 1973, Metabolism: clinical and experimental.

[47]  J. Schwarz,et al.  Hepatic de novo lipogenesis in normoinsulinemic and hyperinsulinemic subjects consuming high-fat, low-carbohydrate and low-fat, high-carbohydrate isoenergetic diets. , 2003, The American journal of clinical nutrition.

[48]  Teven,et al.  MORTALITY FROM CORONARY HEART DISEASE IN SUBJECTS WITH TYPE 2 DIABETES AND IN NONDIABETIC SUBJECTS WITH AND WITHOUT PRIOR MYOCARDIAL INFARCTION , 2000 .

[49]  H. Ginsberg.  Lipoprotein physiology. , 1998, Endocrinology and metabolism clinics of North America.

[50]  A. Hamsten,et al.  Accumulation of large very low density lipoprotein in plasma during intravenous infusion of a chylomicron-like triglyceride emulsion reflects competition for a common lipolytic pathway. , 1996, Journal of lipid research.